U.S., July 18 -- ClinicalTrials.gov registry received information related to the study (NCT07712588) titled 'Birelentinib Plus R-CHOP in Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma (TAI-SHAN19)' on July 14.
Brief Summary: This study will treat patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL). It will assess the anti-tumor efficacy and safety of birelentinib plus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) vs placebo plus R-CHOP.
Study Start Date: Sept., 2027
Study Type: INTERVENTIONAL
Condition:
Diffuse Large B-Cell Lymphoma (DLBCL)
Intervention:
DRUG: Birelentinib
Specified dose on specified days
DRUG: Rituximab
Specified dose on specified days
DRUG: Cyclophos...